209 related articles for article (PubMed ID: 10589748)
1. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Meerum Terwogt JM; Malingré MM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Koopman FJ; van Tellingen O; Swart M; Schellens JH
Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
Malingré MM; Beijnen JH; Rosing H; Koopman FJ; Jewell RC; Paul EM; Ten Bokkel Huinink WW; Schellens JH
Br J Cancer; 2001 Jan; 84(1):42-7. PubMed ID: 11139311
[TBL] [Abstract][Full Text] [Related]
4. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
[TBL] [Abstract][Full Text] [Related]
5. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
6. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
van Asperen J; van Tellingen O; van der Valk MA; Rozenhart M; Beijnen JH
Clin Cancer Res; 1998 Oct; 4(10):2293-7. PubMed ID: 9796957
[TBL] [Abstract][Full Text] [Related]
7. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
[TBL] [Abstract][Full Text] [Related]
8. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
9. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Bardelmeijer HA; Ouwehand M; Malingré MM; Schellens J; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
[TBL] [Abstract][Full Text] [Related]
10. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
[TBL] [Abstract][Full Text] [Related]
11. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
12. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
[TBL] [Abstract][Full Text] [Related]
13. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
Choi BC; Choi JS; Han HK
Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
[TBL] [Abstract][Full Text] [Related]
15. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
Gelderblom H; Verweij J; Brouwer E; Pillay M; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Drug Metab Dispos; 1999 Nov; 27(11):1300-5. PubMed ID: 10534315
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
[TBL] [Abstract][Full Text] [Related]
18. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
Veltkamp SA; Rosing H; Huitema AD; Fetell MR; Nol A; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Oct; 60(5):635-42. PubMed ID: 17205304
[TBL] [Abstract][Full Text] [Related]
19. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
